MedTrace Logo

Insulin Sensitivity After Breast Cancer

NCT05010356 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-08-18

No results posted yet for this study

Summary

Epidemiological studies have revealed that 60-80% of women with breast cancer (BC) develop metabolic disorders that are similar to those observed in conditions like type 2 diabetes. These metabolic disorders, including insulin resistance, obesity, hyperinsulinemia, and glucose intolerance, are associated with increased BC recurrence and mortality. Skeletal muscle is the major site of glucose uptake in humans. The aims of the present project are to 1) determine the involvement of insulin resistance in skeletal muscle in the metabolic disorders prevalent in BC survivors, 2) identify BC-and/or treatment-induced molecular changes in skeletal muscle from BC survivors .

Conditions

  • Insulin Sensitivity/Resistance
  • Breast Cancer
  • Survivorship
  • Metabolic Disturbance

Interventions

DRUG

Insulin

Hyperinsulinemic euglycemic clamp

Sponsors & Collaborators

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Lykke Sylow, PhD · University of Copenhagen

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2022-12-31
Completion
2026-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05010356 on ClinicalTrials.gov